alexa Responding To The Threat Of Emergent Infectious Diseases
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Klaus Schwamborn
Valneva SE, France
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-057
Emerging and re-emerging infectious diseases are a significant and growing threat to life and health of millions of people around the world with recent outbreaks such as Ebola and Zika claiming thousands of lives and costing billions of dollars. Vaccines contributing to outbreak prevention and treatment are the most effective solution to save lives and reduce associated costs. In order to respond quickly and appropriately to current and upcoming emergent infectious diseases Valneva SE has established a vaccine platform that allows the development of highly efficient vaccines for a variety of different viruses in particular for mosquito-borne infectious diseases. Case studies of Zika, chikungunya and yellow fever will be presented demonstrating that the combination of cell culture platforms and other technologies has led to the generation of novel vaccine candidates that are ready to enter clinical development. In this context a vector based NDV approach will also be discussed.

Klaus Schwamborn is currently the Vice President in the Department of Vaccine Research at Valneva SE and serves as the Director of BlinK Biomedical SAS, France. He is involved in finding innovative approaches and technologies to generate novel vaccine candidates. He has also held international positions at Pepscan Therapeutics and Celgene. He has broad experience in drug discovery and research in infectious diseases and oncology including the areas of therapeutics antibodies and peptide based biologics. He received his PhD from the University of Göttingen and completed his Post-doctoral studies from the Institute Pasteur, Paris.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version